Back to top

biotechs: Archive

Zacks Equity Research

What's in the Cards for Viatris Stock This Q4 Earnings?

VTRS' Q4 results are likely to gain from new product launches in all major geographies.

PCRXNegative Net Change VKTXPositive Net Change MIRMNegative Net Change VTRSPositive Net Change

Zacks Equity Research

Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus

PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.

RHHBYPositive Net Change BMYPositive Net Change NVOPositive Net Change PRTAPositive Net Change

Urmimala Biswas

4 Seniors & Aging Demographics Stocks to Watch Right Now

ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.

ABTPositive Net Change AMGNPositive Net Change MDTPositive Net Change SYKNegative Net Change DXCMNegative Net Change ABBVPositive Net Change

Zacks Equity Research

SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates

SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

PCRXNegative Net Change ARGXNegative Net Change SWTXNegative Net Change

Zacks Equity Research

Cassava Gears Up to Report Q4 Earnings: What's in the Cards?

On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.

PCRXNegative Net Change ARGXNegative Net Change SAVANegative Net Change MIRMNegative Net Change

Zacks Equity Research

Repligen's Q4 Earnings Beat Estimates, Revenues In Line

RGEN reports decent fourth-quarter results and issues guidance for 2025.

RGENNegative Net Change PCRXNegative Net Change ARGXNegative Net Change

Zacks Equity Research

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.

PCRXNegative Net Change INSMNegative Net Change ARGXNegative Net Change DAWNPositive Net Change

Zacks Equity Research

Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales

BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.

PCRXNegative Net Change BHCPositive Net Change IMCRPositive Net Change

Zacks Equity Research

FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth

Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.

TEVANegative Net Change FOLDPositive Net Change PCRXNegative Net Change HRMYNegative Net Change

Zacks Equity Research

BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View

BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.

SNYPositive Net Change BMRNNegative Net Change ARGXNegative Net Change DAWNPositive Net Change

Zacks Equity Research

Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up

KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.

BMRNNegative Net Change FOLDPositive Net Change KRYSPositive Net Change CSTLNegative Net Change

Zacks Equity Research

ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?

On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

PCRXNegative Net Change ADMANegative Net Change VKTXPositive Net Change MIRMNegative Net Change

Zacks Equity Research

Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News

MRNA and GILD are in the spotlight this week on fourth-quarter earnings release and regulatory update, respectively.

GILDNegative Net Change MRNAPositive Net Change SLDBNegative Net Change SEPNNegative Net Change

Zacks Equity Research

Novavax to Report Q4 Earnings: Here's What You Can Expect

On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.

SNYPositive Net Change NVAXPositive Net Change TGTXNegative Net Change ARGXNegative Net Change

Zacks Equity Research

HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth

Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.

RHHBYPositive Net Change JNJPositive Net Change HALOPositive Net Change PCRXNegative Net Change

Zacks Equity Research

Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth

AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.

JAZZNegative Net Change PCRXNegative Net Change AXSMPositive Net Change HRMYNegative Net Change

Sundeep Ganoria

CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?

The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

VRTXPositive Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change

Sundeep Ganoria

Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?

Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA stock.

GSKNegative Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Ekta Bagri

Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

BMYPositive Net Change MRKPositive Net Change EXELPositive Net Change

Ahan Chakraborty

Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock

RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the absence of a marketed product.

JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change RXRXNegative Net Change

Ekta Bagri

Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there is more room for growth and recommend the stock to investors.

GSKNegative Net Change MRKPositive Net Change GILDNegative Net Change

Zacks Equity Research

Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.

BMYPositive Net Change PCRXNegative Net Change MIRMNegative Net Change IMCRPositive Net Change

Ahan Chakraborty

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.

BMRNNegative Net Change HALOPositive Net Change FOLDPositive Net Change INSMNegative Net Change AXSMPositive Net Change

Zacks Equity Research

BioMarin to Report Q4 Earnings: Here's What to Expect

When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.

BMRNNegative Net Change TGTXNegative Net Change VKTXPositive Net Change ARGXNegative Net Change

Zacks Equity Research

BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline

Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the announcement.

ALNYNegative Net Change BPMCNegative Net Change IMCRPositive Net Change